- Theralase Technologies (TLT) has closed a non-brokered private placement offering for gross proceeds of approximately $250,000
- The corporation issued a total of 1,000,000 units at $0.25 per unit
- Proceeds will be used for continuing clinical studies
- Theralase is a clinical-stage pharmaceutical company
- Theralase Technologies Inc. (TLT) opened trading at C$0.25
Theralase Technologies (TLT) has closed a non-brokered private placement offering for gross proceeds of approximately $250,000.
The corporation issued a total of 1,000,000 units at $0.25 per unit. Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire an additional share for a period of 24 months.
The company paid a finder’s fee of $1,350 in cash and issued 2,700 finder’s warrants.
Proceeds will be used for the following:
- Good Laboratory Practice toxicology study for Intravenous installation of Rutherrin intended for the treatment of Non-Small Lung Cancer and Gio Blastoma Multiforme
- Advancement of Phase II Non-Muscle Invasive Bladder Cancer clinical study
- Working capital and general corporate purposes
Theralase is a clinical-stage pharmaceutical company.
Theralase Technologies Inc. (TLT) opened trading at C$0.25.
